Edition:
United States

Merck & Co Inc (MRK)

MRK on New York Consolidated

62.53USD
20 Jan 2017
Change (% chg)

$2.20 (+3.65%)
Prev Close
$60.33
Open
$62.40
Day's High
$62.92
Day's Low
$62.15
Volume
25,239,897
Avg. Vol
11,138,722
52-wk High
$65.46
52-wk Low
$47.97

MRK

Chart for MRK

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company's Pharmaceutical segment... (more)

Overall

Beta: 0.78
Market Cap(Mil.): $166,338.09
Shares Outstanding(Mil.): 2,757.14
Dividend: 0.47
Yield (%): 3.12

Financials

  MRK Industry Sector
P/E (TTM): 30.69 29.62 30.50
EPS (TTM): 1.97 -- --
ROI: 6.63 15.43 14.85
ROE: 12.29 16.61 16.27

Merck, Bristol-Myers agree to settle Keytruda patent suit

Merck & Co said it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Co and Ono Pharmaceutical Co Ltd to resolve all global patent-infringement litigation related to its cancer drug, Keytruda.

5:31pm EST

Merck, Bristol-Myers agree to settle Keytruda patent suit

Merck & Co said it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Co and Ono Pharmaceutical Co Ltd to resolve all global patent-infringement litigation related to its cancer drug, Keytruda.

5:22pm EST

UPDATE 1-Merck, Bristol-Myers agree to settle Keytruda patent suit

Jan 20 Merck & Co said it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Co and Ono Pharmaceutical Co Ltd to resolve all global patent-infringement litigation related to its cancer drug, Keytruda.

5:20pm EST

Bristol-Myers lung cancer delay slams shares, keeps Merck in lead

New YORK Bristol-Myers Squibb Co shares fell 11 percent on Friday following Thursday's announcement that it would not seek accelerated approval of its immunotherapy drug combination in first-line lung cancer, further solidifying Merck & Co Inc's leading position in the burgeoning immuno-oncolgy field.

4:53pm EST

UPDATE 1-Bristol-Myers lung cancer delay slams shares, keeps Merck in lead

New YORK, Jan 20 Bristol-Myers Squibb Co shares fell 11 percent on Friday following Thursday's announcement that it would not seek accelerated approval of its immunotherapy drug combination in first-line lung cancer, further solidifying Merck & Co Inc's leading position in the burgeoning immuno-oncolgy field.

4:52pm EST

US STOCKS-Wall St ends higher as Trump takes office

NEW YORK, Jan 20 U.S. stocks closed higher on Friday in a modest but broad-based advance as Donald Trump was sworn in as U.S. President, marking the first time in more than 50 years that a new commander-in-chief has been welcomed by a rising equity market on his first day in office.

4:29pm EST

Merck, Bristol-Myers agree to settle Keytruda patent suit

Jan 20 Merck & Co said it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Co and Ono Pharmaceutical Co Ltd to resolve a patent litigation related to its cancer drug, Keytruda.

4:23pm EST

BRIEF-Merck announces license agreement resolving Keytruda patent litigation

* Merck announces settlement and license agreement resolving Keytruda (pembrolizumab) patent litigation

4:06pm EST

Merck CEO sees Keytruda in pole position in cancer race

DAVOS, Switzerland Merck & Co's Keytruda cancer drug, which last week won a speedy review from U.S. regulators for use with chemotherapy in lung cancer, is in an increasingly strong position in a fiercely competitive market, the company's CEO said on Thursday.

Jan 19 2017

Wall Street ends choppy session higher, health lags on Trump comments

NEW YORK U.S. stocks ended higher after a choppy day on Wednesday as energy and technology gains countered a drop in healthcare stocks after President-elect Donald Trump said pharmaceutical companies were "getting away with murder" by charging high prices. | Video

Jan 11 2017

Competitors

Earnings vs. Estimates